ArticleBMJ (Clinical research ed.)2020
Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017.
Article in BMJ (Clinical research ed.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05934617 (Trajectories of FEV1 After Lung Transplantation), which is not on this map. Cited by 189 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Trajectories of FEV1 After Lung Transplantation: Determinants and Clinical Outcomes
Who cites it
189 citing papers in PubMed, 7 syntheses or guidelines pooled it, 385 citations in OpenAlex.
- Comparative efficacy of digital health interventions and traditional mind-body exercises for pulmonary rehabilitation in chronic obstructive pulmonary disease: a systematic review and network meta-analysis.Frontiers in medicine · 2026Pooled it
- Pooled it
- Global, regional, and national burden of chronic respiratory diseases and associated risk factors, 1990-2019: Results from the Global Burden of Disease Study 2019.Frontiers in medicine · 2023Pooled it
- Greenness and chronic respiratory health issues: a systematic review and meta-analysis.Frontiers in public health · 2023Pooled it
- The clinical efficacy of type 2 monoclonal antibodies in eosinophil-associated chronic airway diseases: a meta-analysis.Frontiers in immunology · 2023Pooled it
- Effectiveness of Hospital Pharmacist Interventions for COPD Patients: A Systematic Literature Review and Logic Model.International journal of chronic obstructive pulmonary disease · 2022Pooled it
- Pooled it
- Management of COPD and comorbidities in COPD patients by dispensing pharmaceutical care following Global Initiative for Chronic Obstructive Lung Disease-guidelines (GOLD guidelines 2020): a prospective randomized clinical trial.BMC health services research · 2026Trial
- Impact of pharmacist-led intervention in medication adherence and inhaler usage on asthma and chronic obstructive pulmonary disease control: a quasi-experimental study.BMC health services research · 2024Trial
- Respiratory Effects of Traffic-Related Air Pollution: A Randomized, Crossover Analysis of Lung Function, Airway Metabolome, and Biomarkers of Airway Injury.Environmental health perspectives · 2023Trial
- Prevalence of abnormal spirometry and correlates of lung function decline among a population in rural Uganda.Journal of global health · 2026Article
- Creb3l1 Overexpression Improves Flexor Tendon Repair in Aged Rats.Aging cell · 2026Article
- SWORD survey: Seasonal trends in hospitalisation and mortality among patients with respiratory illnesses in India.Lung India : official organ of Indian Chest Society · 2026Article
- Relationship between asthma, obesity and other comorbidities: the Australasian Severe Asthma Registry.Respiratory research · 2026Article
- Protective Effects of Hypericum orientale L. Extracts Against Cigarette Smoke-Induced Bronchial Cytotoxicity and Respiratory Pathogens.Chemistry & biodiversity · 2026Article
- Predictor of Mortality in Obstructive Sleep Apnea: Results of Explainable Deep Learning-Based Survival Analysis from a 15-Year Follow-Up.Respiration; international review of thoracic diseases · 2026Article
- Effects of Manual Therapy on Respiratory Function in Healthy Individuals: A Randomized, Sham-Controlled Clinical Trial of Efficacy and Safety.Healthcare (Basel, Switzerland) · 2026Article
- Prevalence and Spatial Distribution of Chronic Respiratory Diseases in Dar es Salaam, Tanzania: Hydrological and Household Influences.GeoHealth · 2026Article
- Educational interventions during the hospitalisation of patients with chronic respiratory disease: A systematic review.International journal of nursing studies advances · 2026Review
- National, Subnational, and Risk-Attributed Burden of Chronic Respiratory Diseases in Iran (1990-2021): A Longitudinal Clustering Analysis of Global Burden of Disease 2021 Data.Health science reports · 2026Article
129 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the temporal and spatial trends of mortality and disability adjusted life years (DALYs) due to chronic respiratory diseases, by age and sex, across the world during 1990-2017 using data from the Global Burden of Disease Study 2017.
designSystematic analysis. DATA SOURCE: The Global Burden of Diseases, Injuries, and Risk Factors Study 2017.
methodsMortality and DALYs from chronic respiratory diseases were estimated from the Global Burden of Disease Study 2017 using DisMod-MR 2.1, a Bayesian meta-regression tool. The estimated annual percentage change of the age standardised mortality rate was calculated using a generalised linear model with a Gaussian distribution. Mortality and DALYs were stratified according to the Socio-demographic index. The strength and direction of the association between the Socio-demographic index and mortality rate were measured using the Spearman rank order correlation. Risk factors for chronic respiratory diseases were analysed from exposure data.
resultsBetween 1990 and 2017, the total number of deaths due to chronic respiratorydiseases increased by 18.0%, from 3.32 (95% uncertainty interval 3.01 to 3.43) million in 1990 to 3.91 (3.79 to 4.04) million in 2017. The age standardised mortality rate of chronic respiratory diseases decreased by an average of 2.41% (2.28% to 2.55%) annually. During the 27 years, the annual decline in mortality rates of chronic obstructive pulmonary disease (COPD; 2.36%, uncertainty interval 2.21% to 2.50%) and pneumoconiosis (2.56%, 2.44% to 2.68%) has been slow, whereas the mortality rate for interstitial lung disease and pulmonary sarcoidosis (0.97%, 0.92% to 1.03%) has increased. Reductions in DALYs for asthma and pneumoconiosis have been seen, but DALYs due to COPD, and interstitial lung disease and pulmonary sarcoidosis have increased. Mortality and the annual change in mortality rate due to chronic respiratory diseases varied considerably across 195 countries. Assessment of the factors responsible for regional variations in mortality and DALYs and the unequal distribution of improvements during the 27 years showed negative correlations between the Socio-demographic index and the mortality rates of COPD, pneumoconiosis, and asthma. Regions with a low Socio-demographic index had the highest mortality and DALYs. Smoking remained the major risk factor for mortality due to COPD and asthma. Pollution from particulate matter was the major contributor to deaths from COPD in regions with a low Socio-demographic index. Since 2013, a high body mass index has become the principal risk factor for asthma.
conclusionsRegions with a low Socio-demographic index had the greatest burden of disease. The estimated contribution of risk factors (such as smoking, environmental pollution, and a high body mass index) to mortality and DALYs supports the need for urgent efforts to reduce exposure to them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.